Hepatic Glycogenosis: An Underdiagnosed Entity?

Sofia Garcês Soares 1, Renato Medas 2, Filipe Conceição 3, Roberto Silva 4, José Artur Paiva 3, Ana Cristina Carneiro 3

Abstract

Hepatic glycogenosis (HG) is a rare complication of long-standing poorly controlled type 1 diabetes mellitus (T1DM), which is often misdiagnosed as non-alcoholic fatty liver disease (NAFLD). Despite the existence of several reports in the literature, it still is underrecognized, even among gastroenterologists. Differential diagnosis between these entities is essential since they have different prognoses.

We report a case of an 18-year-old female, with a medical history of poorly controlled T1DM, admitted to an intensive care unit with severe diabetic ketoacidosis (DKA). Upon admission, aminotransferases were significantly elevated; bilirubin and coagulation tests were normal. Despite adequate DKA treatment, she had persistently elevated aminotransferases and hyperlactacidemia. Imaging studies showed hepatomegaly and bright liver parenchyma. Extensive laboratory workup was negative for other causes of liver disease. So, a liver biopsy was performed, which was consistent with the diagnosis of HG. Under strict metabolic control, she had progressive improvement, achieving biochemical normalization within 6 months.

This case highlights the need for clinicians to be aware of this condition due to non-negligible differences between HG and NAFLD, with the latter progressing to fibrosis, and ultimately cirrhosis and hepatocarcinoma. On the opposite, HG is considered a benign condition, associated with an excellent prognosis that can be reversible after adequate metabolic control. Liver biopsy remains the gold standard method for HG diagnosis since it can distinguish it from NAFLD.

Introduction

Hepatic glycogenosis (HG) is a rare complication of long-standing poorly controlled type 1 diabetes mellitus (T1DM) due to excessive intrahepatic glycogen accumulation. It was first described in 1930 by Pierre Mauriac in children with poorly controlled T1DM presenting with hepatomegaly with abnormal liver enzymes, poor growth, delayed puberty, cushingoid features, and hypercholesterolemia as the Mauriac Syndrome [1]. Later, several case reports described the presence of HG without the full spectrum of Mauriac Syndrome, both in adolescents and young adults with T1DM and less commonly with type 2 diabetes mellitus (T2DM) [2].

HG is still an underrecognized entity, even among gastroenterologists, and it is often misdiagnosed as non-alcoholic fatty liver disease (NAFLD) due to its similar presentation and difficult distinction based on clinical, biochemical, and radiological findings [3]. Differential diagnosis between these entities is important since they have different prognoses. NAFLD can progress to advanced fibrosis, liver cirrhosis, and hepatocarcinoma. In contrast, HG is considered a benign condition, without significant fibrosis and it can be reversible after adequate metabolic control [4]. Liver biopsy remains the gold standard test to make the differential diagnosis between HG and NAFLD, due to its unique pathologic features [5].

Case Presentation

We describe a case of an 18-year-old female, with a medical history of poorly controlled T1DM due to noncompliance with insulin therapy with 5 years of evolution. She presented in the emergency department with a 2-day history of upper abdominal pain, nausea, vomiting, and hyperglycemia (819 mg/dL). She denied fever, bowel transit changes, or consumption of hepatotoxins. She reported insulin pump malfunction over the last month.

On physical examination, she had no cushingoid facies and had a normal BMI (23.7 kg/m²). She was polyneptic (respiratory rate 30), normotensive, tachycardic (heart rate 145 bpm), apyretic, and had a tender palpable liver. Laboratory workup revealed severe metabolic acidemia (pH 7.07, pO2 130.4 mmHg, pCO2 10.4 mmHg, HCO3 2.9 mEq/L, AG 29.3, lactates 4.16), leukocytosis and neutrophilia, cholestasis,
transaminitis, and ketonuria. C-reactive protein (CRP), renal function, ionogram, bilirubin, and coagulation test were normal (Table 1). Abdominal ultrasound was positive for marked hepatomegaly (20 cm long axis) without focal lesions or biliary tract dilatation. Glycated hemoglobin (HbA1c) was 10.0%. So, the diagnosis of severe diabetic ketoacidosis (DKA) was made, and she was admitted to the intensive care unit (ICU) for prompt treatment with insulin perfusion.

| Parameter          | Results   | Reference value |
|--------------------|-----------|-----------------|
| Hemoglobin         | 14.5 g/dL | 12.0–16.0       |
| Leukocytes         | 25.62×10⁹/L | 4.0–11.0       |
| Neutrophils        | 75.2%     | 53.8–69.8       |
| C-reactive protein | 9.4 mg/L  | <3.0            |
| Platelets          | 582×10⁹ /L | 150–400         |
| Urea               | 50 mg/dL  | 10–50           |
| Creatinine         | 1.01 mg/dL | 0.51–0.95       |
| Sodium             | 133 mEq/L | 135–147         |
| Potassium          | 5.0 mEq/L | 3.5–5.1         |
| Chlorides          | 94 mEq/L  | 101–109         |
| GOT                | 227 U/L   | 10–31           |
| GPT                | 339 U/L   | 10–31           |
| GGT                | 122 U/L   | 7–32            |
| ALP                | 248 U/L   | 30–120          |
| Total bilirubin    | 0.60 mg/dL | <1.20         |
| LDH                | 418 U/L   | 135–225         |
| Amylase            | 30 U/L    | 22–80           |
| Lipase             | 5 U/L     | 7–60            |
| Albumin            | 35 g/L    | 38.0–51.0       |
| aPTT               | 21.6 seg  | 24.2–36.4       |
| PT                 | 12.6 seg  | 9.6–13.6        |
| Fibrinogen         | 481 mg/dL | 200–400         |
| Ketonuria          | 60 mg/dL  | <10             |
| Total cholesterol  | 204 mg/dL | <200            |
| HDL cholesterol    | 55 mg/dL  | >60             |
| Calculated LDL cholesterol | 109 mg/dL | <130      |
| Triglycerides      | 200 mg/dL | <150            |
| HbA1c              | 10%       | 4.0–6.0         |
| TSH                | 1.6 Ul/mL | 0.35–5.00       |
| Free T4            | 0.86 ng/dL | 0.88–1.58    |
| IgA                | 192 mg/dL | 78–312          |
| IgM                | 74 mg/dL  | 55–300          |
| IgG                | 945 mg/dL | 650–1500        |
| Antinuclear antibodies | 1/100  | <1/100          |
Antimitochondrial antibodies | Negative | -
---|---|---
Anti-smooth muscle antibodies | Negative | -
CMV IgG antibody | 134.6 AU/mL | <6.0
CMV IgM antibody | Negative | -
EBV VCA IgM antibody | Negative | -
EBV IgG antibody (Early) | <0.2 RU/mL | Negative < 0.9
EBV IgG antibody (EBNA) | >8.0 RU/mL | Uncertain 0.9–1.1
EBV IgG antibody (VCA) | >8.0 RU/mL | Positive >= 1.1
Heterophile antibodies | Negative | -
HIV 1 /2 antibodies | Negative | -
HBV antibodies | Negative | -
HCV antibodies | Negative | -
Ceruloplasmin | 23.4 mg/dL | 18.0–45.0
Alpha-1 antitrypsin | 95.4 mg/dL | 103.0–202.0

**TABLE 1: Laboratory diagnostic workup**

GOT: glutamate oxaloacetate transaminase; GPT: glutamic pyruvic transaminase; GGT: gamma-glutamyl transferase; ALP: alkaline phosphatase; LDH: lactate dehydrogenase; aPTT: activated partial thromboplastin time; PT: prothrombin time; HDL cholesterol: high-density lipoprotein cholesterol; calculated LDL cholesterol: calculated low-density cholesterol; TSH: thyroid-stimulating hormone; Free T4: free thyroxine; IgA: immunoglobulin A; IgM: immunoglobulin M; IgG: immunoglobulin G; CMV: cytomegalovirus; EBV: Epstein-Barr virus; HIV: human immunodeficiency virus; HBV: hepatitis B virus; HCV: hepatitis C virus

Despite the resolution of DKA in less than 24 hours upon admission, cholestasis, transaminitis, hyperlactacidemia (8.4 mmol/L), and abdominal pain persisted, which prompted a further workup.

An abdominopelvic computed tomography angiography scan (Figure 1) confirmed hepatomegaly with bright parenchyma and revealed a hemorrhagic cyst in the left ovary (2.5 cm). A transvaginal ultrasound excluded an ovarian torsion. Workups for hepatitis A, B, C, and E viruses, cytomegalic (CMV) and Epstein-Barr viruses (EBV), human immunodeficiency virus (HIV), autoimmune hepatitis, alpha-1 antitrypsin deficiency, hemochromatosis, Wilson’s disease, and celiac disease were negative (Table 1).

**FIGURE 1: Cross (A) and coronal (B) sections of abdominopelvic computed tomography angiography revealing hepatomegaly**

A percutaneous liver biopsy was performed, which showed diffusely swollen hepatocytes with abundant and pale cytoplasm and thickened plasma membranes (paved appearance of liver parenchyma), multifocal nuclear glycogenization, and absence of fibrosis, consistent with the diagnosis of HG (Figures 2–3).
FIGURE 2: Liver histology

Periodic acid–Schiff (PAS) stain showing large quantities of glycogen in the cytoplasm of hepatocytes (A). PAS with diastase (PAS-D) led to the digestion of cytoplasmatic glycogen, resulting in empty hepatocytes ("ghost cells") (B), helping to differentiate glycogen from other PAS-positive elements in tissue samples.
After three days, she was transferred from the ICU to the endocrinology ward. Under strict metabolic control, she showed progressive biochemical improvement, being discharged home six days later under a basal-bolus insulin regimen. She maintained a close follow-up and had an improvement in glycemic control (HbA1c 7.8%) and normalization of liver tests 6 months later.

**Discussion**

The true incidence and prevalence of HG are unknown, but it is thought to be underestimated due to unawareness of this disease, even among gastroenterologists. One reason for that, it is the difficulty in its differential diagnosis with NAFLD, often leading to misdiagnosis [6]. The incidence of HG decreased significantly since the introduction of long-acting insulin and due to the growing recognition and awareness of glycemic control by diabetic patients and their caregivers, but it still exists [7].

Most reported cases of HG occurred in T1DM patients, while only ~2% were associated with T2DM [8]. In opposition, NAFLD is less common in T1DM, with an estimated prevalence lower than in the general population and it is 2-fold higher than in the general population in T2DM patients [9]. Other conditions were associated with HG such as dumping syndrome, anorexia nervosa, high-dose glucocorticoid use, and insulin overdose [8].

The exact mechanism responsible for HG is not fully understood, but wide fluctuations in glucose and insulin levels that can occur in diabetic patients with poor metabolic control may play an important role. The synthesis of hepatic glycogen is the consequence of the combination of high blood glucose levels (which promote the flow of glucose into hepatocytes) and hyperinsulinemia (which stimulates the conversion of glucose to glycogen) [10,11]. However, it is not understood why only some patients have the potential to develop HG.

Albeit initially described in children, several reports described this entity in adults (without the full spectrum of Mauriac Syndrome). So, HG can appear at any age, although most cases occur in adolescence, with a slight predominance in females (~62%) [8]. Clinical presentation of HG varies from an asymptomatic elevation of liver enzymes to hyperglycemia-related symptoms such as polyuria, polydipsia, weight loss, and lethargy, and other symptoms such as abdominal pain, nausea, vomiting, and anorexia. HG is often seen in patients with frequent episodes of DKA (abdominal pain, nausea, and vomiting) [8].

The most common finding on physical examination is hepatomegaly without splenomegaly, which is present in more than 90% of the reported cases. Rapid enlargement of the liver may cause visceral pain secondary to Glisson’s capsule stretching [8]. Rarely, ascites may be present due to sinusoidal compression by swollen hepatocytes [12]. Our patient presented only with tender hepatomegaly, which may reflect a rapid hepatic
glycogen accumulation due to malfunction of the insulin pump and poor glycemic control. The occurrence of DKA was probably the trigger to develop elevation of liver enzymes.

Laboratory workup often presents mild to moderate elevation in liver aminotransferases, with a predominant elevation of glutamate oxaloacetate transaminase (GOT) over glutamic pyruvic transaminase (GPT) (ratio GOT/GPT >1). Most reported cases showed a hepatocellular pattern, although a mixed pattern or even a cholestatic pattern can rarely occur. Reversal of the elevation of aminotransferases (up to 100× the upper limit of normal) have been reported, generally in patients presenting with DKA. Dehydration in this setting may have a role in such elevation due to transient liver hypoperfusion. Albeit rare, elevation of ALT can also occur as we have seen in our patient. Liver function is usually preserved.

Our patient had persistent hyperlactacidemia despite adequate treatment of DKA. Persistently elevated lactic acid can be seen in patients with HG who present with DKA without hypoperfusion. The exact mechanism is unclear. A reduction in gluconeogenesis in the liver may raise lactate levels in the body. Therefore, lactic acidosis in HG could be explained by reduced gluconeogenesis with inhibition of the conversion of pyruvate to glucose and shifting its metabolism to lactate.

Diagnosis can be difficult because laboratory and imaging tests are not pathognomonic. It includes the exclusion of other causes of liver damage: infectious (hepatitis B virus (HBV), hepatitis A virus (HAV), and hepatitis C virus (HCV)), metabolic (Wilson disease, hemochromatosis), obstructive diseases, autoimmune diseases, and drugs. It is essential to test for autoimmune antibodies (antinuclear antibodies (ANA), anti-smooth muscle, and antimitochondrial) as there is an association between T1DM and autoimmune hepatitis. This patient had only slightly positive ANA. HG and glycogen storage disease (GSD) can present similarly, so differentiating between them by genetic testing is important considering they have wide differences in their management. However, GSD often presents in the neonatal period or early infancy.

Once excluded from the above causes, the main differential diagnosis is NALFD which presentation can be similar to HG. Imaging studies may help to reach the correct diagnosis, however, they have several limitations. Abdominal ultrasound is not useful to distinguish them, since in both cases it shows hepatomegaly and increased echogenicity of liver parenchyma. Sweetser suggested that a bright liver on a CT scan (compared to the spleen), without the administration of contrast, can help in the differential diagnosis. A hyperdense liver may be seen in HG, compared to a hypodense liver in NALFD. However, the difference may be subtle and only provides qualitative information. Neither abdominal US nor CT scan is a useful imaging method for the definitive diagnosis of HG. Gradient dual-echo magnetic resonance imaging (MRI) has been reported to be helpful in differentiating HG from NALFD. HG presents with hypointense or isointense on T2-weighted images and hyperintense on T1-weighted images. In NALFD, in-phase and out-of-phase gradient T1-weighted images demonstrate signal dropout on the out-of-phase image due to the presence of fat deposition in the liver. If there is no significant difference in the signal intensities between the two phases, then the results are not consistent with intrahepatic fat storage and are more consistent with HG.

Due to the inaccuracy of non-invasive methods, liver biopsy remains the gold standard for HG diagnosis. The timing for performing the biopsy is not defined in the literature, but it is known that this is the only way to diagnose HG and it is the only way to distinguish it from NALFD. The fact that this patient maintained, despite the resolution of the DKA, abdominal pain, cholestasis, transaminitis, and hyperlactacidemia, led to the fear of possible organ dysfunction, leading to an early biopsy. Hematoxylin and eosin (H&E) stain shows pale and swollen hepatocytes, thickened plasma membranes, increased cytoplasmic volume, and glycogenotic nuclei (empty nuclei with ring-like chromatin elements). A mosaic or paved appearance of liver parenchyma may be seen due to sinusoidal compression of swollen hepatocytes. Periodic acid-Schiff (PAS) stain is positive as it stains glycogen. The addition of diastase will cause enzymatic breakdown of glycogen, leading to empty hepatocytes, also called "ghost cells." Typically, the architecture of liver parenchyma remains intact. Most cases show no or minimal portal inflammation, steatosis, or fibrosis. However, recent reports described the presence of variable degrees of fibrosis including bridging fibrosis.

Conclusions
In conclusion, the overall prognosis of HG is excellent, being reversible after adequate metabolic control. The authors consider that it is important to be aware of this condition since it has a simple and effective treatment. Given the huge differences in prognosis between HG and NAFLD, liver biopsy is mandatory to ascertain the diagnosis and, more importantly, to avoid misdiagnosis.

In addition, it is important to keep in mind that this is a possible cause of liver enzyme changes in patients with poorly controlled DM and that it often goes unnoticed.

### Additional Information

#### Disclosures

**Human subjects:** Consent was obtained or waived by all participants in this study.

**Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following:

- **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work.
- **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.
- **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

### References

1. Mauriac P: Gros ventre, hépatomégalie, troubles de la croissancechez les enfants diabétiques traités depuis plusieurs années par l’insuline. Gaz Heb Med Bordeaux. 1950, 26:402-10.

2. Silva M, Marques M, Cardoso H, et al.: Glycogenic hepatopathy in young adults: a case series. Rev Esp Enferm Dig. 2016, 108:675-6. 10.17255/reed.2016.3954/2015

3. Abaci A, Bekem O, Unuvar T, et al.: Hepatic glycogenosis: a rare cause of hepatomegaly in type 1 diabetes mellitus. J Diabetes Complications. 2008, 22:325-8. 10.1016/j.jdc.2007.11.002

4. Al Sarkhy AA, Zaidi ZA, Bablizer AM: Glycogenic hepatopathy, an undiagnosed complication of relapsing hepatitis in uncontrolled type 1 diabetes mellitus. Saudi Med J. 2017, 38:89-92. 10.1557/smj.2017.1.15954

5. Angulo P: Nonalcoholic fatty liver disease. N Engl J Med. 2002, 346:1221-31. 10.1056/NEJMra011775

6. Giordano S, Martocchia A, Toussan L, et al.: Diagnosis of hepatic glycogenosis in poorly controlled type 1 diabetes mellitus. World J Diabetes. 2014, 5:882-8. 10.4259/wjd.v5.i6.882

7. Gutch M, Philip R, Saran S, Tyagi R, Gupta KR: Re-emergence of a rare syndrome: a case of mauriac syndrome. Indian J Endocrinol Metab. 2015, 17:283-5. 10.4103/2230-8210.119611

8. Sherigar JM, Castro J, Yin YM, Goss D, Mohanty SR: Glycogenic hepatopathy: a narrative review. World J Hepatol. 2018, 10:172-85. 10.4254/wjh.v10.i2.172

9. Younossi ZM, Golabi P, de Avila L, et al.: The global epidemiology of NAFLD and NASI in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019, 71:795-801. 10.1001/jhep.2019.06.021

10. Munns CF, McCrossin RB, Thomsett MJ, Batch J: Hepatic glycogenosis: reversible hepatomegaly in type 1 diabetes. J Paediatr Child Health. 2000, 36:449-52. 10.1046/j.1440-1754.2000.00547.x

11. Julián MT, Alonso N, Gijonure R, Pizarro E, Ballester E, Puig-Domingo M: Hepatic glycogenosis: an underdiagnosed complication of diabetes mellitus?. World J Diabetes. 2015, 6:321-2. 10.4259/wjd.v6.i2.321

12. Torbenson M, Chen YY, Brunt E, et al.: Glycogenic hepatopathy: an underrecognized hepatic complication of diabetes mellitus. Am J Surg Pathol. 2006, 30:508-13. 10.1097/00000478-200604000-00012

13. Haffar S, Izzy M, Habib H, et al.: Liver chemistries in glycogenic hepatopathy associated with type 1 diabetes mellitus: a systematic review and pooled analysis. Liver Int. 2021, 41:1545-55. 10.1111/liv.14827

14. Martin J, Tomlinson P: Hepatic complications in poorly controlled type 1 diabetes mellitus: a case report. N Z Med J. 2014, 127:97-5-7.

15. Khoury J, Zohar Y, Sheldahen N, Saadi T: Glycogenic hepatopathy. Hepatobiliary Pancreat Dis Int. 2018, 17:115-8. 10.1016/j.hbpdi.2018.02.006

16. Deemer KS, Alvarez GF: A rare case of persistent lactic acidosis in the ICU: glycogenic hepatopathy and Mauriac syndrome. Case Rep Crit Care. 2016, 2016:1-5. 10.1155/2016/6072909

17. Jeppesen JB, Mortensen C, Bendtzen F, Müller S: Lactate metabolism in chronic liver disease. Scand J Clin Lab Invest. 2015, 75:293-9. 10.3109/00365513.2015.773591

18. Burda P, Hochuli M: Hepatic glycogen storage disorders: what have we learned in recent years? Curr Opin Clin Nutr Metab Care. 2015, 18:415-21. 10.1097/MCO.0000000000000181

19. Regan JA, Golubski B, Gilbert EB, Sullivan B, McCall SJ, Sata SS: Glycogenic hepatopathy causing elevated lactic acid and liver enzymes. Am J Med. 2020, 133:191-4. 10.1016/j.amjmed.2019.07.018

20. Sweetser S, Kraichely RE: The bright liver of glycogenic hepatopathy. Hepatology. 2010, 51:711-2. 10.1002/hep.25402

21. Murata F, Horie I, Ando T, et al.: A case of glycogenic hepatopathy developed in a patient with new-onset fulminant type 1 diabetes: the role of image modalities in diagnosing hepatic glycogen deposition including gradient-dual-echo MRI. Endocr J. 2012, 59:669-76. 10.1507/endocrj.E12-0081

22. Li Q, Dhyani M, Grajo JR, Sirlin C, Samir AE: Current status of imaging in nonalcoholic fatty liver disease. World J Hepatol. 2018, 10:530-42. 10.4254/wjh.v10.i8.530

23. Muchewar S, Sharma A, Lackore KA, et al.: Clinical, biochemical, and histopathologic features of patients with glycogenic hepatopathy. Clin Gastroenterol Hepatol. 2017, 15:927-35. 10.1016/j.cgh.2016.11.038

24. Huang DQ, El-Serag HB, Chalasani NP, Goggins WC, Powell JA, Cummings OW: Complete reversal of glycogenic hepatopathy with pancreas transplantation: two cases. Transplantation. 2007, 83:84-6. 10.1097/01.tp.0000239510.27872.07
26. Messeri S, Messerini L, Vizzutti F, Laffi G, Marra F: Glycogenic hepatopathy associated with type 1 diabetes mellitus as a cause of recurrent liver damage. Ann Hepatol. 2012, 11:554-8. 10.1016/S1665-2681(19)31472-3